- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05661201
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
March 7, 2024 updated by: Georgetown University
Phase I Study of NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and how well it works in patients with advanced/unresectable or metastatic solid KRAS-mutated and ST-positive solid tumors.
The main question it aims to answer is to find the recommended dose and scheduled for the combination of NEROFE and doxorubicin.
Participants will receive weekly doses of NEROFE and doxorubicin.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jennifer Montcalm
- Phone Number: 202-687-8974
- Email: jem257@georgetown.edu
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Recruiting
- Georgetown Lombardi Comprehensive Cancer Center
-
Contact:
- Jennifer Montcalm
- Phone Number: 202-687-8974
- Email: jem257@georgetown.edu
-
Principal Investigator:
- Benjamin Weinberg, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Advanced/unresectable or metastatic solid tumor with a pathogenic KRAS mutation via polymerase chain reaction (PCR), next-generation sequencing (NGS), or other standard test (blood-based DNA testing is allowed)
- Presence of tumor ST2 expression via immunochemistry assay
- Progression or intolerance to all standard therapies, patient may decline standard therapies and retain eligibility (patients must not have available curative options)
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
Laboratory inclusion criteria:
- Absolute neutrophil count ≥ 1500/mm3
- Hemoglobin ≥ 9.0 g/dL (transfusions are allowed to achieve this inclusion criterion)
- Platelets ≥ 100 x 109/L (transfusions are NOT allowed to achieve this inclusion criterion)
- Creatinine clearance ≥ 50 mL/min/1.73 m2 using the formula: creatinine clearance = [[140 - age(yr)]*weight(kg)]/[72*serum Cr(mg/dL)] (multiply by 0.85 for women).
- AST and ALT ≤ 3 x the upper limit of normal of the institution's normal range and total bilirubin ≤ 1.5 x the upper limit of normal of the institution's normal range - if liver metastases are present, AST and ALT ≤ 5 x the upper limit of normal of the institution's normal range and total bilirubin ≤ 3 x the upper limit of normal of the institution's normal range unless there is persistent nausea, vomiting, right upper quadrant pain, fever, rash, or eosinophilia
- Partial Thromboplastin Time (PTT) must be ≤ 1.5 × upper limit of normal of institution's normal range and INR (International Normalized Ratio) < 1.5. Subjects on anticoagulation (such as warfarin) will be permitted to enroll as long as the INR is in the acceptable therapeutic range as determined by the investigator
- Patients must have fully recovered from all effects of surgery. Patients must have had at least two weeks after minor surgery and four weeks after major surgery before starting therapy. Minor procedures requiring "twilight" sedation such as endoscopies or mediport placement may only require a 24-hour waiting period, but this must be discussed with an investigator
- Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential
- Patient is capable of understanding and complying with parameters as outlined in the protocol and able to sign and date the informed consent, approved by the Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures
- Have measurable disease by RECIST v. 1.1
- Have disease amenable to serial core tumor biopsies
- Suitable, stable venous access to allow for all study-related blood sampling (a central line such as a portacath (e.g. Medi-Port) or PICC is highly encouraged)
Exclusion Criteria:
- Age < 18 years
- Prior exposure to anthracycline chemotherapy
- Receiving any active anti-cancer therapy while on study treatment
- Brain metastases unless they have been previously treated with surgery and/or radiation at least 4 weeks prior to C1D1 and have a baseline MRI that shows no evidence of active/progressing intracranial disease
- Anti-tumor therapy within 3 weeks of C1D1 (defined as, but not limited to, cytotoxic chemotherapy, immunotherapy, biological therapy, radiotherapy, and investigational agents), the "wash-out period"
- Concurrent severe illness or uncontrolled medical condition that, in the investigator's judgement, would cause unacceptable safety risks
- Women who are pregnant or breastfeeding
- Concurrent use of an aromatase inhibitor
- Psychiatric illness or social situation that would limit compliance with study requirements
- Concurrent malignancy or malignancy within 2 years prior to starting study drug, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer, or a malignancy that the investigator deems has been definitively treated (e.g. early stage prostate cancer)
- Active hepatitis B, C, or HIV (patients with hepatitis C infection are eligible if they have an undetectable viral load following definitive treatment, patients with HIV are eligible if they have an undetectable viral load and a CD4 count above 500 cells/mm3)
Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormalities, including any of the following:
- History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within 6 months prior to screening
- History of documented congestive heart failure (New York Heart Association functional classification III-IV)
- Documented cardiomyopathy
- Left Ventricular Ejection Fraction (LVEF) <50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening
- Clinically significant cardiac arrhythmias (e.g. ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g. bifascicular block, Mobitz type II and third-degree AV block)
- QTcF (using Fridericia's correction) of > 480 msec
Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
- Risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia.
- Concomitant use of medication(s) with a known risk to prolong the QT interval and/or known to cause Torsades de Pointe that cannot be discontinued (within 5 half-lives or 7 days prior to starting study drug) or replaced by safe alternative medication
- Inability to determine the QT interval on screening (QTcF, using Fridericia's correction)
- Systolic blood pressure (SBP) >160 mmHg or <90 mmHg at screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Level 1: NEROFE with doxorubicin
weekly doses of NEROFE at 96 mg/m2, intravenously over 60 minutes
|
weekly doses of NEROFE (48-288 mg/m2) (dose level 1: 96 mg/m2, dose level -1: 48 mg/m2, dose level 2: 192 mg/m2, dose level 3: 288 mg/m2), intravenously over 60 minutes
weekly doses of 8 mg/m2 (fixed dose), intravenous push over 3 mins;
Other Names:
|
Experimental: Dose level -1: Nerofe with doxorubicin
weekly doses of NEROFE at 48 mg/m2, intravenously over 60 minutes
|
weekly doses of NEROFE (48-288 mg/m2) (dose level 1: 96 mg/m2, dose level -1: 48 mg/m2, dose level 2: 192 mg/m2, dose level 3: 288 mg/m2), intravenously over 60 minutes
weekly doses of 8 mg/m2 (fixed dose), intravenous push over 3 mins;
Other Names:
|
Experimental: Dose level 2: Nerofe with doxorubicin
weekly doses of NEROFE at 192 mg/m2, intravenously over 60 minutes
|
weekly doses of NEROFE (48-288 mg/m2) (dose level 1: 96 mg/m2, dose level -1: 48 mg/m2, dose level 2: 192 mg/m2, dose level 3: 288 mg/m2), intravenously over 60 minutes
weekly doses of 8 mg/m2 (fixed dose), intravenous push over 3 mins;
Other Names:
|
Experimental: Dose Level 3: Nerofe with doxorubicin
weekly doses of NEROFE at 288 mg/m2, intravenously over 60 minutes
|
weekly doses of NEROFE (48-288 mg/m2) (dose level 1: 96 mg/m2, dose level -1: 48 mg/m2, dose level 2: 192 mg/m2, dose level 3: 288 mg/m2), intravenously over 60 minutes
weekly doses of 8 mg/m2 (fixed dose), intravenous push over 3 mins;
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: Cycle 1 Day 1 until 30 days following discontinuation of study drug, approximately 6 months.
|
Safety and tolerability of NEROFE and doxorubicin in patients with advanced KRAS-mutated and ST2-positive solid tumors
|
Cycle 1 Day 1 until 30 days following discontinuation of study drug, approximately 6 months.
|
Incidence of Serious Adverse events
Time Frame: From time of Consent until 30 days following discontinuation of study drug, approximately 6 months.
|
Safety and tolerability of NEROFE and doxorubicin in patients with advanced KRAS-mutated and ST2-positive solid tumors
|
From time of Consent until 30 days following discontinuation of study drug, approximately 6 months.
|
Incidence of Adverse events meeting protocol defined dose limiting toxicities
Time Frame: Cyce 1 Day 1 through 28 days
|
Safety and tolerability of NEROFE and doxorubicin in patients with advanced KRAS-mutated and ST2-positive solid tumors
|
Cyce 1 Day 1 through 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic (PK): AUC (area under the curve) 0-24 hours
Time Frame: 24 hours, on Cycle 1 Day 1 and Cycle 2 Day 1 (each cycle is 28 days)
|
Pharmacokinetics of NEROFE and doxorubicin in patients with advanced KRAS-mutated and ST2-positive solid tumors; AUC 0-24 hours calculated using the trapezoidal rule [(Concentration at 0 hour + concentration at 24 hours) x 24]/2
|
24 hours, on Cycle 1 Day 1 and Cycle 2 Day 1 (each cycle is 28 days)
|
Pharmacokinetic: Cmax
Time Frame: 24 hours, on Cycle 1 Day 1 and Cycle 2 Day 1 (each cycle is 28 days)
|
Pharmacokinetics of NEROFE and doxorubicin in patients with advanced KRAS-mutated and ST2-positive solid tumors; maximum 24 hour concentration
|
24 hours, on Cycle 1 Day 1 and Cycle 2 Day 1 (each cycle is 28 days)
|
Pharmacokinetic: Cmin
Time Frame: 24 hours, on Cycle 1 Day 1 and Cycle 2 Day 1 (each cycle is 28 days)
|
Pharmacokinetics of NEROFE and doxorubicin in patients with advanced KRAS-mutated and ST2-positive solid tumors; minimum 24 hours concentration
|
24 hours, on Cycle 1 Day 1 and Cycle 2 Day 1 (each cycle is 28 days)
|
Pharmacokinetic: Tmax
Time Frame: 24 hours, on Cycle 1 Day 1 and Cycle 2 Day 1 (each cycle is 28 days)
|
Pharmacokinetics of NEROFE and doxorubicin in patients with advanced KRAS-mutated and ST2-positive solid tumors; hour at which Cmax occurs
|
24 hours, on Cycle 1 Day 1 and Cycle 2 Day 1 (each cycle is 28 days)
|
Pharmacokinetic: t1/2
Time Frame: 24 hours, on Cycle 1 Day 1 and Cycle 2 Day 1 (each cycle is 28 days)
|
Pharmacokinetics of NEROFE and doxorubicin in patients with advanced KRAS-mutated and ST2-positive solid tumors; the time at which the concentration is at half its initial value
|
24 hours, on Cycle 1 Day 1 and Cycle 2 Day 1 (each cycle is 28 days)
|
Pharmacodynamics: Change in ST2 expression
Time Frame: pretreatment to Cycle 2 Day 15 (each cycle is 28 days)
|
Pharmacodynamics of NEROFE and doxorubicin in patients with advanced KRAS--mutated and ST2-positive solid tumors; Change in ST2 expression by IHC will be quantified by percentage of positively stained cells in pre- vs. on-treatment tumor biopsies
|
pretreatment to Cycle 2 Day 15 (each cycle is 28 days)
|
Pharmacodynamics: Change in KRAS mRNA
Time Frame: pretreatment to Cycle 2 Day 15 (each cycle is 28 days)
|
Pharmacodynamics of NEROFE and doxorubicin in patients with advanced KRAS-mutated and ST2-positive solid tumors; Change in KRAS mRNA will be quantified by qPCR in blood and tissue (pre- vs. on-treatment blood samples and tumor biopsies).
|
pretreatment to Cycle 2 Day 15 (each cycle is 28 days)
|
Progression free survival (PFS)
Time Frame: 6 months
|
time from the date of the initial treatment to the date of first documented disease progression or death due to any cause, whichever occurs first.
|
6 months
|
Overall Survival (OS)
Time Frame: 2 years 6 months
|
Overall Survival (OS): defined as the date of the initial treatment to the date of the participant's death.
|
2 years 6 months
|
Overall Response Rate (ORR)
Time Frame: every 8 weeks until progression, approximately 6 months
|
The proportion of participants who achieve a PR or better according to the RECIST version 1.1 criteria.
|
every 8 weeks until progression, approximately 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Benjamin Weinberg, MD, Georgetown University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 12, 2023
Primary Completion (Estimated)
January 1, 2026
Study Completion (Estimated)
January 1, 2026
Study Registration Dates
First Submitted
November 28, 2022
First Submitted That Met QC Criteria
December 13, 2022
First Posted (Actual)
December 22, 2022
Study Record Updates
Last Update Posted (Actual)
March 12, 2024
Last Update Submitted That Met QC Criteria
March 7, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00005711
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
Clinical Trials on NEROFE
-
Immune System Key LtdCompleted
-
Immune System Key LtdUniversity of Miami Sylvester Comprehensive Cancer CenterRecruitingAML | Advanced MDSUnited States
-
VastBiomeRecruitingRenal Cell Carcinoma | Non-Small-Cell Lung Carcinoma | Malignant Melanoma | Triple-Negative Breast CancerUnited States
-
Immune System Key LtdWithdrawnMyelodysplastic Syndromes | Acute Myelogenous LeukemiaIsrael
-
University of British ColumbiaCompleted
-
Immune System Key LtdWithdrawnTriple Negative Breast Cancer | Metastatic Ovarian CancerIsrael